期刊
THROMBOSIS AND HAEMOSTASIS
卷 117, 期 9, 页码 1798-1807出版社
SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
DOI: 10.1160/TH16-10-0799
关键词
Acetylsalicylic acid; ticagrelor; clopidogrel; endotoxaemia; platelet inhibition
资金
- AstraZeneca
The use of acetylsalicylic acid (ASA) is associated with improved outcome in patients with sepsis, and P2Y(12) inhibitors have been suggested to also have immunomodulatory effects. Therefore, we evaluated the effects of clinically relevant combinations of antiplatelet therapy on the immune response in experimental endotoxaemia in humans in vivo. Forty healthy subjects were randomised to seven days of placebo, placebo with ASA, ticagrelor and ASA, or clopidogrel and ASA treatment. Systemic inflammation was elicited at day seven by intravenous administration of Escherichia coli endotoxin. ASA treatment profoundly augmented the plasma concentration of pro-inflammatory cytokines, but did not affect anti-inflammatory cytokines. Addition of either P2Y(12) antagonist to ASA did not affect any of the circulating cytokines, except for an attenuation of the ASA-induced increase in TNF alpha by ticagrelor. Systemic inflammation increased plasma adenosine, without differences between groups, and although P2Y(12) inhibition impaired platelet reactivity, there was no correlation with cytokine responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据